XML 43 R22.htm IDEA: XBRL DOCUMENT v3.24.3
EARNINGS PER SHARE
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.
The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information):
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Net Income for Earnings Per Share Calculations:
Income from continuing operations, net of tax$362.1 $334.9 $1,051.0 $886.9 
Net loss attributable to noncontrolling interests(1.4)(1.2)(3.6)(2.8)
Income from continuing operations attributable to Edwards Lifesciences Corporation363.5 336.1 1,054.6 889.7 
Income from discontinued operations2,707.3 48.8 2,734.4 142.8 
Net income attributable to Edwards Lifesciences Corporation$3,070.8 $384.9 $3,789.0 $1,032.5 
Weighted Average Shares:
Basic weighted-average shares outstanding597.2 607.0 600.3 607.2 
Dilutive effect of stock plans0.9 2.5 1.9 3.0 
Dilutive weighted-average shares outstanding598.1 609.5 602.2 610.2 
Earnings per Share:
Basic:
Continuing operations$0.61 $0.55 $1.76 $1.47 
Discontinued operations4.53 0.08 4.55 0.23 
Basic earnings per share$5.14 $0.63 $6.31 $1.70 
Diluted:
Continuing operations$0.61 $0.55 $1.75 $1.46 
Discontinued operations4.52 0.08 4.54 0.23 
Diluted earnings per share$5.13 $0.63 $6.29 $1.69 

Stock options, restricted stock units, and market-based restricted stock units to purchase an aggregate of 10.4 million and 6.5 million common shares for the three months ended September 30, 2024 and 2023, respectively, and 7.8 million and 6.1 million shares for the nine months ended September 30, 2024 and 2023, respectively, were outstanding, but were not included in the computation of diluted earnings per share for such periods because the effect would have been anti-dilutive. Additionally, 1.9 million shares that would have been received if the ASR agreement discussed in Note 12 was settled as of September 30, 2024 were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive.